HDP-101 demonstrated complete response in one female patient from cohort 5 R&D Webinar to be hosted on 17 June 2025 Ladenburg, Germany, 14 May 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it will be presenting new clinical data on its lead Amanitin-based […]
Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology breakthrough properties for its PAR2 biased negative allosteric modulator program Posters present the potential of GPCRs to modulate the tumor microenvironment and enhance anti-tumor immunity Strasbourg, France – Montreal, […]
Edinburgh and London, UK, 10 December 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company focused on pioneering regenerative macrophage therapy (“RMT”) in inflammatory and fibrotic diseases, today announces it has presented a poster at the Keystone Symposia Fibrosis: Inflammation, Drivers, and Therapeutic Resolution taking place on 8 – 11 December 2024 in […]
– Complete 3-year clinical data from the MATCH Phase 2 study demonstrate long-term efficacy and safety with autologous, non-engineered macrophages in patients with advanced liver cirrhosis. – New preclinical data support superior anti-inflammatory and anti-fibrotic effect of RTX001, an engineered macrophage investigational therapy, compared to non-engineered macrophages. – RTX001 has recently entered into a Phase […]
– Oral Presentation of complete data from the three-year MATCH Phase 2 trial – Poster Presentation demonstrating preclinical proof of concept of safety and efficacy of RTX001, an autologous engineered macrophage cell therapy for end stage liver disease Edinburgh and London, UK, 1 October 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company […]
